Skip to main content

Research resources

This page contains research resources related to developing vaccine studies and therapeutics and other research resources below. Follow the development of the various SARS-COV-2 vaccines with the Coronavirus Vaccine Tracker managed by The New York Times.

Go to therapeutics.
Go to vaccine studies.
Go to other research resources.

Research resources: Therapeutics

NETEC COVID-19 Webinar Series (11/25/20): Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility

Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility (November 25, 2020)

NETEC COVID-19 Webinar Series (11/18/20): COVID-19 Therapeutics

COVID-19 Therapeutics (November 18, 2020)

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: EUA of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Heath Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab

Fact Sheet for Heath Care Providers: EUA of Bamlanivimab

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

act Sheet for Health Care Providers: EUA of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of VEKLURY® (remdesivir) for Hospitalized Pediatric Patients weighing 3.5 kg to less than 40 kg OR Hospitalized Pediatric Patients less than 12 years of age weighing at least 3.5 kg.

Fact Sheet for Health Care Providers: EUA of VEKLURY® (remdesivir) for Hospitalized Pediatric Patients

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Health Care Providers: EUA of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Healthcare Providers: REGIOCIT (Sodium Chloride and Sodium Citrate Renal Replacement and Regional Anticoagulant solution)

Fact Sheet for Healthcare Providers: REGIOCIT

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Fact Sheet for Health Care Providers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 — Final Report

Remdesivir for the Treatment of Covid-19 — Final Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Mild/Moderate 2019-nCoV Remdesivir RCT

Mild/Moderate 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Adaptive COVID-19 Treatment Trial (ACTT)

Adaptive COVID-19 Treatment Trial (ACTT)

Vaccine Studies:

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years...

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV...

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine...

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report...

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older...

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Other Research resources:

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

Share this page: